Invion Ltd has released a press release.
Animal studies show IVX-P02 potential in metastatic cancers
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Invion
- Quarterly Update
- Appendix 4D and Financial Report for Half Year to 31 Dec 18
- Response to ASX Appendix 4C Query
- Invion completes spin-out of respiratory assets
- General Meeting - Results of Meeting
Later from Invion
- Appendix 4C - June quarter
- COO Craig Newton to transition to Invion CEO
- Appendix 4E and Financial Report for year ended 30 June 2019
- Appendix 4C - September 2019 quarter
- Pre-clinical research agreement with Peter MacCallum CC
Follow Invion into a list and get an email when it puts out news.
Follow Invion